ArticleNature metabolism2023
Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity.
Open access · greenAbstract read
In one paragraph
Article in Nature metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 41 citations in OpenAlex.
- The GPCRDiabetologia · 2026Article
- Glycemic and bodyweight effects ofScience advances · 2026Article
- Discerning protein pools by selective staining with self-labeling tags.FEBS letters · 2026Review
- Recent developments in GPCR signalling in appetite regulation.Bioscience reports · 2026Review
- Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis.Circulation research · 2026Review
- Adissp activates insulin-independent glucose disposal and energy expenditure in white fat to treat diabetes and cardiometabolic disease.Science advances · 2026Article
- Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart.Pharmaceutics · 2026Review
- The genetics of obesity: aetiology, prevention and therapy.Nature metabolism · 2026Review
- Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure.International journal of molecular sciences · 2026Review
- The evolving landscape of pharmacogenomics: Current achievements and future directions.Pharmacological reviews · 2026Review
- In vivo functional profiling and structural characterization of the humanScience advances · 2026Article
- GLP-1RA precision medicine in people with type 2 diabetes: current insights and future prospects.The Journal of clinical investigation · 2026Review
- Multi-faceted roles of β-arrestins in G protein-coupled receptor endocytosis.Nature communications · 2025Article
- Expression and functional diversity of the glucagon-like peptide-1 receptor across tumor types.Discover oncology · 2025Article
- Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases.Journal of nanobiotechnology · 2025Review
- Glucagon-like Peptide-1 Receptor (GLP-1R) Signaling: Making the Case for a Functionally GInternational journal of molecular sciences · 2025Review
- Rare MTNR1B variants causing diminished MT2 signalling associate with elevated HbADiabetologia · 2025Article
- Obesity: exploring its connection to brain function through genetic and genomic perspectives.Molecular psychiatry · 2025Review
- Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose-High-Lipid Conditions: A Comparative Study.International journal of molecular sciences · 2025Article
- GLP-1 and the Neurobiology of Eating Control: Recent Advances.Endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 5 institutions in 5 countries.
Wenwen GaoUniversité Paris Cité, Institut Cochin, INSERM, CNRS, Paris, France.ORCID 0009-0007-6209-0493
Lei LiuUniversité Paris Cité, Institut Cochin, INSERM, CNRS, Paris, France.ORCID 0000-0002-9824-9570
Eunna HuhDepartment of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX, USA.
Florence GbahouUniversité Paris Cité, Institut Cochin, INSERM, CNRS, Paris, France.
Erika CeconUniversité Paris Cité, Institut Cochin, INSERM, CNRS, Paris, France.
Masaya OshimaUniversité Paris Cité, Institut Cochin, INSERM, CNRS, Paris, France.
Ludivine HouzéUniversité Paris Cité, Institut Cochin, INSERM, CNRS, Paris, France.
Panagiotis KatsonisDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Alan HegronUniversité Paris Cité, Institut Cochin, INSERM, CNRS, Paris, France.ORCID 0000-0002-7588-9209
Zhiran FanCellular Signaling Laboratory, International Research Center for Sensory Biology and Technology of MOST, Key Laboratory of Molecular Biophysics of Ministry of Education, School of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.
Guofei HouCellular Signaling Laboratory, International Research Center for Sensory Biology and Technology of MOST, Key Laboratory of Molecular Biophysics of Ministry of Education, School of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.
Guillaume CharpentierCERITD (Centre d'Étude et de Recherche pour l'Intensification du Traitement du Diabète), Evry, France.
Mathilde BoisselUniversity of Lille, Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, Lille University Hospital, Lille, France.ORCID 0000-0001-5719-8749
Mehdi DerhourhiUniversity of Lille, Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, Lille University Hospital, Lille, France.ORCID 0000-0001-5020-5379
Michel MarreInstitut Necker-Enfants Malades, INSERM, Université Paris Cité, Paris, France.
Beverley BalkauInserm U1018, Center for Research in Epidemiology and Population Health, Villejuif, France.ORCID 0000-0003-2021-413X
Philippe FroguelUniversity of Lille, Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, Lille University Hospital, Lille, France.ORCID 0000-0003-2972-0784
Raphael ScharfmannUniversité Paris Cité, Institut Cochin, INSERM, CNRS, Paris, France.ORCID 0000-0001-7619-337X
Olivier LichtargeDepartment of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX, USA.
Julie DamUniversité Paris Cité, Institut Cochin, INSERM, CNRS, Paris, France.ORCID 0000-0001-6871-2678
Amélie BonnefondUniversity of Lille, Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, Lille University Hospital, Lille, France.
Jianfeng LiuCellular Signaling Laboratory, International Research Center for Sensory Biology and Technology of MOST, Key Laboratory of Molecular Biophysics of Ministry of Education, School of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China. jfliu@mail.hust.edu.cn.ORCID 0000-0002-0284-8377
Ralf JockersUniversité Paris Cité, Institut Cochin, INSERM, CNRS, Paris, France. ralf.jockers@inserm.fr.ORCID 0000-0002-4354-1750
Centre National de la Recherche Scientifique · FRBaylor College of Medicine · USHuazhong University of Science and Technology · CNInserm · FRCentre d'Etudes et de Recherches pour l'Intensification du Traitement du Diabète · FR
Funding
Functional Determinnats in G Protein-coupled ReceptorsR01GM066099 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI LICHTARGE, OLIVIER · 2003 to 2022
$7.5MNIGMS NIH HHS R01 GM066099
Abstract
The glucagon-like peptide 1 receptor (GLP1R) is a major drug target with several agonists being prescribed in individuals with type 2 diabetes and obesity
Indexed as
Blood GlucoseDiabetes Mellitus, Type 2AdiposityHumansInsulinObesityBlood GlucoseInsulin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.